Business Context and Reporting Period
Company: Stratasys Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Filing Date: November 15, 2016
Reporting Period: Three and nine months ended September 30, 2016 (Q3 2016)
This filing incorporates by reference the company's unaudited, condensed consolidated financial statements and management's review of results of operations for the specified periods.
Key Financial Metrics
The provided text serves as a cover document and index for the financial results. It does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the attached exhibits (Exhibit 99.1 and Exhibit 99.2) which are referenced but not included in the input text.
Material Changes
The filing text does not provide specific data regarding material changes versus prior comparable periods. The document indicates that a "Review of Results of Operations" is attached as Exhibit 99.2, where such comparisons would be detailed.
Guidance, Outlook, and Risks
- Outlook: The filing references an "Operating and Financial Review and Prospects" section within Exhibit 99.2, but no specific guidance or outlook statements are present in the cover text.
- Risks and Contingencies: The filing references "Quantitative and Qualitative Disclosures About Market Risk" and a "Legal Proceedings Update" within Exhibit 99.2. No specific risks or legal details are disclosed in the provided text.
- Unusual Items: No unusual items are described in the cover document.
Investor Verification Checklist
- Verify the specific revenue and net income figures for the three and nine months ended September 30, 2016, in Exhibit 99.1.
- Review the "Operating and Financial Review and Prospects" in Exhibit 99.2 for management's commentary on year-over-year performance and future guidance.
- Examine the "Legal Proceedings Update" in Exhibit 99.2 for any new or ongoing litigation risks.
- Confirm the details of market risk disclosures regarding foreign currency or interest rate exposure in Exhibit 99.2.